2024-10-14 2024-10-14 , online online, 1,190 € plus tax Dr. Penelope Gallinger https://www.forum-institut.com/seminar/24112002-amnog-and-the-eu-hta-insights-into-the-german-market/referenten/24/24_11/24112002-amnog-and-the-eu-hta-insights-into-the-german-market_gallinger-penelope.jpg AMNOG and the EU HTA - Insights into the German Market

This seminar will focus on AMNOG and JCA dossier preparation as well as the German AMNOG procedure in comparison with the EU HTA procedure.

Topics

The AMNOG dossier: storyline and demonstration of evidence
The EU JCA dossier in comparison with the AMNOG dossier
Early benefit assessment at the G-BA and subsequent price negotiation
The EU HTA process in detail

Who should attend

This seminar addresses the needs of employees in the pharmaceutical industry who require profound insight into AMNOG, the German HTA procedure, and knowledge of the upcoming EU HTA procedure. It is intended for market access beginners as well as marketing and medical affairs specialists who need extensive know-how in this field.

Aims and objectives

Are you involved in the market access of innovative drugs in Germany? Do you need to understand the main principles involved, especially in comparison with the upcoming EU HTA procedure?

Then this seminar will familiarise you with the main tasks and hurdles along the way. Three outstanding market access experts will guide you through the procedure and can answer your questions on both the national and the EU level.

Your benefit

Knowledge of the German market concerning the market access of innovative drugs.
The ability to support market access in Germany in terms of dossier preparation and process know-how.
The ability to anticipate the upcoming changes as a result of the EU HTA.

24112002 Seminar AMNOG and the EU HTA - Insights into the German Market

AMNOG and the EU HTA - Insights into the German Market

Benefits

JCA dossier and AMNOG dossier
AMNOG and EU HTA procedure in comparison
Officially certified to the ISO 9001 and ISO 21001 standards

Webcode 24112002

Book now

JETZT Buchen

Speakers

Everything at a glance

Appointment

27/11/2024

27/11/2024

Period

9:00 am - 5:00 pm seminar
You may dial in 30 minutes in advance

9:00 am - 5:00 pm seminar
You may dial in 30 minutes in advance

Venue

online

online

Downloads

Fee

Inhouse-offers

Your contact

24112002 Seminar AMNOG and the EU HTA - Insights into the German Market

Dr. Henriette Wolf-Klein
Head of Department

+49 6221 500-680
h.wolf-klein@forum-institut.de

Details

This seminar will focus on AMNOG and JCA dossier preparation as well as the German AMNOG procedure in comparison with the EU HTA procedure.

Topics

The AMNOG dossier: storyline and demonstration of evidence
The EU JCA dossier in comparison with the AMNOG dossier
Early benefit assessment at the G-BA and subsequent price negotiation
The EU HTA process in detail

Who should attend

This seminar addresses the needs of employees in the pharmaceutical industry who require profound insight into AMNOG, the German HTA procedure, and knowledge of the upcoming EU HTA procedure. It is intended for market access beginners as well as marketing and medical affairs specialists who need extensive know-how in this field.

Aims and objectives

Are you involved in the market access of innovative drugs in Germany? Do you need to understand the main principles involved, especially in comparison with the upcoming EU HTA procedure?

Then this seminar will familiarise you with the main tasks and hurdles along the way. Three outstanding market access experts will guide you through the procedure and can answer your questions on both the national and the EU level.

Your benefit

Knowledge of the German market concerning the market access of innovative drugs.
The ability to support market access in Germany in terms of dossier preparation and process know-how.
The ability to anticipate the upcoming changes as a result of the EU HTA.

Detailed programme

9:00 am - 5:00 pm seminar
You may dial in 30 minutes in advance

09:00 Welcome and introduction

09:15

Dr Penelope Gallinger

The AMNOG Dossier - the key essentials

Strategic planning, the key essentials
Dossier structure and templates
Module 3 - storyline and therapeutic value and benefits
Module 4 - demonstration of evidence
The crucial points: the appropriate comparative therapy and the biostatistical analysis of the study groups

10:15 Short break

10:25

Dr Penelope Gallinger

Continuation: The AMNOG Dossier - the key essentials

11:30 Coffee break

11:45

Dr Penelope Gallinger, Dr Vanessa Elisabeth Schaub

The EU HTA dossier (JCA dossier) in comparison with the AMNOG dossier

The JCA dossier structure at a glance
Commonalities and differences in comparison with the AMNOG dossier
How to handle various PICO schemes in Europe - pre-specification options
Real-life insights from a company that prepares dossiers

13:00 Lunch break

14:00

Dr Penelope Gallinger, Dr Martin Granser

The AMNOG procedure

Early benefit assessment at the G-BA - first contact, scientific advice, comment procedure and hearing
Price negotiation at the GKV-Spitzen-verband - what can be negotiated, payment terms and the challenge for drugs in combination with others

15:45 Coffee break

16:00

Dr Vanessa Elisabeth Schaub

The EU HTA procedure in comparison - what will change

Start of the HTA process in parallel with the marketing authorisation procedure
The EU HTA process in detail
Challenge: changes in the marketing authorisation approval process

17:00 End of seminar

Further information

Technical requirements

You need a reliable Internet connection to take part in our online events. To have the best possible learning experience, we recommend that you use the latest version of the Microsoft Edge or Google Chrome browsers. You will need a headset, loudspeaker or telephone to play the audio. Further information is available here. Please check beforehand that your microphone or headset and camera are working properly. Do not access our services from a VPN since there are issues with the audio over such connections.

We have integrated Zoom video conferencing software into our Learning Space for our online training courses. If you are not authorised to use Zoom, please get in touch with us so we can make alternative arrangements for you to take part in our online training.

This distinguishes our events

4,3

of 5 stars of all ratings from 2023

4,2

of 5 stars on Trustpilot = good

Recommendations

An Introduction for Pharmacovigilance Managers

Are you new to pharmacovigilance and looking to kick-start your career? Then this online course is just for you. Gain a ...

12. - 13.11.2024, Online

Details

Drug Market Access & Pricing in Europe

Online seminar on Market Access & Pricing in Europe - this is how you can gain access as a pharmaceutical manufacturer!

10. - 11.12.2024, Online

Details

Mastering ICH Quality Guidelines: From Development to Lifecycle Management

To make the most of ICH Q12 opportunities, you have to be aware of the relation between ICH guidelines Q8 to Q12 and how...

28.11.2024, Online

Details

Regulatory Lifecycle Management

This course familiarises you with regulatory post-approval duties and provides first-hand information on variation submi...

11.12.2024, Online

Details

RMP and PSUR in lifecycle management: An art, not a miracle

- GVP Module XVI Risk minimisation measures (Rev 3) came into force - Do you already have a good understanding of PSUR a...

06.11.2024, Online

Details

Go forward

Our international course portfolio

Are you interested in our international continuous education programme? We provide a variety of specialised courses.

Details

Our international course portfolio

We guarantee the highest quality

We are now officially certified to ISO 9001 and ISO 21001 standard.

Details

Our rating in 2023

More than 4,500 customers have rated our training courses. Thank you for awarding us 4.3 stars out of 5.

Details

Our rating in 2023